Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Summary

Our project is going to enroll patients with stage IV NSCLC with EGFR mutation and evaluate whether primary tumor resection after receiving the afatinib can prolong survival. This project is supposed to establish a new treatment protocol for stage IV NSCLC with EGFR mutation.

Timeline

Start

2021-09-27

Primary completion

2026-10

Completion

2027-10

Drugs

Indications